Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Patrick Dumont
Centre Hospitalier - Chauny
Chauny
France
Contact
Centre Hospitalier - Chauny
Email
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
186
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Weekly Paclitaxel Plus Bevacizumab versus Docetaxel As Second- or Third-Line Treatment in Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC): Results of the IFCT-1103 ULTIMATE Study
Number of pages: 37
Posted: 29 Jun 2019
Alexis Cortot
,
Clarisse Audigier-Valette
,
Olivier Molinier
,
Sylvestre Le Moulec
,
Fabrice Barlesi
,
Gerard Zalcman
, Patrick Dumont,
Damien Pouessel
,
Claire Poulet
,
Sandrine Hiret
,
Adrien Dixmier
,
Patrick-Aldo Renault
,
Catherine Becht
,
Olivier Raffy
,
Charles Dayen
,
Julien Mazieres
,
Eric Pichon
,
Alexandra Langlais
,
Franck Morin
,
Denis Moro-Sibilot
and
Benjamin Besse
Université de Lille - Thoracic Oncology Department, CHITS Sainte Musse, Centre Hospitalier Général - Le Mans, Bergonié Institute, Aix Marseille Université, Hopital Bichat Claude Bernard, Centre Hospitalier - Chauny, University of Paris - Saint Louis Hospital, Centre Hospitalier Universitaire Lyon Sud, Institut de Cancérologie de l'Ouest, Centre Hospitalier Régional Orleans, Centre Hospitalier - Pau, Clinique de Clémentville, Centre Hospitalier Louis Pasteur, Centre Hospitalier - Saint Quentin, Hôpital Larrey, François Rabelais University - CHU Bretonneau - CHU Hôpitaux De Tours, Intergroupe Francophone de Cancérologie Thoracique, Intergroupe Francophone de Cancérologie Thoracique, CHU Grenoble-Alpes and Comité de Pathologies Thoraciques
Downloads
186
(407,391)
View PDF
Download
Abstract:
NSCLC, paclitaxel, docetaxel, bevacizumab
Feedback